49,241 Shares in Prestige Consumer Healthcare Inc. $PBH Acquired by Emerald Investment Advisers LLC

Key Points

• Emerald Investment Advisers acquired 49,241 shares of Prestige Consumer Healthcare, valued at approximately $2.33 million, giving it a 0.10% stake. Institutional investors collectively own 99.95% of the company.
• Analyst sentiment is mixed, with two Buy, three Hold, and one Sell rating. The stock carries an average “Hold” rating and a consensus price target of $70.75 after Canaccord cut its target to $72.
• Prestige exceeded quarterly expectations, reporting $0.98 in EPS versus $0.89 expected and revenue of $265.71 million, up 6.5% year over year. Shares opened at $51.26, near the lower end of their 12-month range.

Emerald Investment Advisers LLC bought a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 49,241 shares of the company's stock, valued at approximately $2,328,000. Emerald Investment Advisers LLC owned about 0.10% of Prestige Consumer Healthcare at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. UMB Bank n.a. raised its holdings in shares of Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company's stock worth $26,000 after buying an additional 219 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at $29,000. Versant Capital Management Inc grew its holdings in shares of Prestige Consumer Healthcare by 47.9% during the second quarter. Versant Capital Management Inc now owns 726 shares of the company's stock valued at $34,000 after buying an additional 235 shares during the last quarter. Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company's stock valued at $35,000 after acquiring an additional 236 shares during the period. Institutional investors and hedge funds own 99.95% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on PBH shares. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research report on Friday, May 15th. Weiss Ratings downgraded Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, June 25th. Oppenheimer lowered Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a report on Thursday, May 14th. Finally, Zacks Research upgraded Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research note on Monday, August 10th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Hold" and an average target price of $70.75.

Prestige Consumer Healthcare Stock Up 1.5%

PBH stock opened at $51.26 on Friday. The company has a market capitalization of $2.43 billion, a P/E ratio of 14.36, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. Prestige Consumer Healthcare Inc. has a 12 month low of $42.62 and a 12 month high of $71.07. The firm's fifty day simple moving average is $49.72 and its 200-day simple moving average is $55.11. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.09. The firm had revenue of $265.71 million during the quarter, compared to analysts' expectations of $253.02 million. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The firm's revenue was up 6.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.56 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source